Ovid Therapeutics Q2 2022 net loss $14.6M; cash $152.4M; OV329 IND on track for H2 2022

Ovid Therapeutics Inc.

2022-Q2 EPS reported -$0.44 revenue$1,445,366

Net loss $14.6M ($0.21 per share) vs $15.8M loss ($0.23) in Q2 2021.
Cash, equivalents & marketable securities $152.4M, expected to fund pipeline into 2025.
R&D expenses $6.0M (down from $7.7M) due to discontinuation of OV101 study and Takeda termination.
OV329 IND submission and Phase 1 start planned for H2 2022; preclinical data shown at epilepsy meetings.
KCC2 activator IND expected in 2024; Takeda reiterates soticlestat regulatory filing in FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.